U.S.A. Food and Drug Administration (FDA) decision on sotatercept for the treatment of pulmonary arterial hypertension expected end March 2024

Merck (known as MSD outside of the US and Canada), announced on Setpember 28 that that the U.S. Food and Drug Administration (FDA) has accepted to give priority review for sotatercept, Merck’s novel investigational activin signaling inhibitor, for the treatment of adult patients with pulmonary arterial hypertension. The FDA has set a target action date of March 26, 2024.

See also our articles on the Stellar clinical study at this link

Source: Merck/MSD company press release